Menu Search
Equities

Creo Medical Group PLC

1RC:DEU

Creo Medical Group PLC

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Creo Medical Group PLC grew revenues 13.36% from 27.17m to 30.80m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -26.94m to -21.70m.
Gross margin49.50%
Net profit margin-73.93%
Operating margin-82.84%
Return on assets-28.35%
Return on equity-38.49%
Return on investment-32.89%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Creo Medical Group PLC fell by 10.10m. Cash Flow from Financing totalled 29.80m or 96.75% of revenues. In addition the company used 21.60m for operations while cash used for investing totalled 18.30m.
Cash flow per share-0.0531
Price/Cash flow per share--
Book value per share0.1311
Tangible book value per share0.0614
More ▼

Balance sheet in GBPView more

Creo Medical Group PLC has a Debt to Total Capital ratio of 23.05%, a higher figure than the previous year's 8.12%.
Current ratio3.24
Quick ratio2.38
Total debt/total equity0.2996
Total debt/total capital0.2305
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.